Tag - ALGS

Executive Moves

Dr. Ramón Polo joins Aligos as SVP, head of global and regulatory affairs

Aligos Therapeutics (NASDAQ: ALGS) has announced the appointment of Ramón Polo, PharmD, PhD, MBA as senior vice president, head of global regulatory affairs, effective immediately. Dr. Polo’s extensive background...

August 21, 2025

Markets

SVB cuts Aligos to market perform; PT to $3 from $7

SVB Securities downgraded Aligos Therapeutics (NASDAQ:ALGS) to “market perform” from “outperform” and slashed its price target to $3, which is close to cash, from $7, citing a slow catalyst path ahead with a legal...

May 5, 2022

Feature

Aligos Therapeutics targeting functionally curative HBV regimen

Even though a number of antiviral medications are in use to treat chronic hepatitis B virus (HBV) infections, Aligos Therapeutics (NASDAQ:ALGS) is going one step further with a portfolio of drug candidates in clinical...

October 19, 2021

Markets

SVB Leerink starts Aligos Therapeutics at OP; PT $29

SVB Leerink initiated coverage of Aligos Therapeutics (NASDAQ:ALGS) with an “outperform” rating and $29 price target. The stock closed at $15.31 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that Aligos is unique among...

September 9, 2021

Tag - ALGS

Dr. Ramón Polo joins Aligos as SVP, head of global and regulatory affairs

SVB cuts Aligos to market perform; PT to $3 from $7

Aligos Therapeutics targeting functionally curative HBV regimen

SVB Leerink starts Aligos Therapeutics at OP; PT $29

Subscribe